In-depth article on Elypta in 360Dx

The Horizon 2020 award announcement has led to increased interest in Elypta’s activities. 360Dx interviewed Karl Bergman (CEO) and Saeed Dabestani, Urologic surgeoun at Skåne University Hospital, senior associate at the European Association of Urology, Guidelines panel for RCC and medical advisor to Elypta on the application of the technology in RCC. Full article here.

Karl Bergman
Elypta awarded €2.35 million from Horizon 2020 SME instrument

Elypta today announced it is one of the winners in the European Union’s Horizon 2020 Research and Innovation Programme SME instrument phase 2 and has been awarded Euros 2.35 m. The grant will fund the first ever multicenter trial for diagnoses of renal cell carcinoma (RCC), aimed at validating the company's innovative metabolism-based liquid biopsy platform for early detection of recurrent RCC and thus enabling the test to be launched in Europe and the US.

Swedish press release

Select press coverage:

Nordic Life Science

Life Science Sweden

360Dx

Labiotech.eu

Karl Bergman